Turnstone Biologics Corp. (TSBX)
| Market Cap | 11.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.42M |
| Shares Out | 23.13M |
| EPS (ttm) | -3.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,533 |
| Open | 0.462 |
| Previous Close | 0.462 |
| Day's Range | 0.431 - 0.491 |
| 52-Week Range | 0.403 - 5.750 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 4.75 (+867.22%) |
| Earnings Date | Nov 12, 2024 |
About TSBX
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of sol... [Read more]
Financial Performance
In 2023, Turnstone Biologics's revenue was $19.31 million, a decrease of -73.66% compared to the previous year's $73.30 million. Losses were -$55.24 million, 78.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TSBX stock is "Buy." The 12-month stock price forecast is $4.75, which is an increase of 867.22% from the latest price.
News
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinica...
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCR...
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operati...
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-tr...
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to trea...
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to trea...
Turnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tr...
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors pre...
Turnstone Biologics to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tre...
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tre...
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with in...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Posters showcase Turnstone's novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone's continued advancement of its Selected TIL therapies
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...
Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...
FMR LLC Acquires Significant Stake in Turnstone Biologics Corp
On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Fin...
Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range
Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offe...
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure ...
IPO Update: Turnstone Biologics Readies $75 Million IPO Plan
Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major pa...
Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each
Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced ...
Turnstone Biologics Begins $86 Million U.S. IPO Plan
Turnstone Biologics has filed to raise $86 million in a U.S. IPO, although the final figure may differ. The company is developing treatment candidates for various cancers. TSBX is still in Phase 1 saf...